

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claims 1-24 (canceled)

Claim 25 (currently amended): A method of treating a patient with a cancer that has a BCRP-mediated resistance to an anticancer agent, which comprises administering the anticancer agent to the patient and preventing or reversing the BCRP-mediated resistance to the anticancer agent by administering co-administering to the patient an effective BCRP-inhibiting amount of imatinib or a pharmaceutically acceptable salt thereof.

Claim 26 (previously presented) A method of claim 25 wherein the cancer that has a BCRP-mediated resistance to an anticancer agent is an osteosarcoma.

Claim 27 (previously presented) A method of claim 25 wherein the anticancer agent is a camptothecin-derived topoisomerase I inhibitor.

Claim 28 (withdrawn) A method of claim 25 wherein the cancer is selected from the group consisting of colon cancer, breast cancer, liver cancer, ovarian cancer, fibrosarcoma, myeloma, acute myeloid leukemia, gastric cancer and non-small cell lung cancer.

Claim 29 (new) A method of claim 27 wherein the camptothecin-derived topoisomerase I inhibitor is selected from the group consisting of topotecan and irinotecan.

Claim 30 (new) A method of claim 25 wherein the anticancer agent is an anthracycline cytotoxic agent.

Claim 31 (new) A method of claim 30 wherein the anticancer agent is selected from the group consisting of mitoxantrone and doxorubicin.